Product image of Jalra (Vildagliptin) supplied by GNH India

Jalra

Active Ingredient:
Vildagliptin
Origin:
EU

Jalra (Vildagliptin)

Vildagliptin, the active ingredient in Jalra, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving glycaemic control when used with diet and exercise.
GNH India supplies Jalra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Novartis Europharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Jalra, a DPP‑4 inhibitor, is used in the management of type 2 diabetes mellitus and related therapeutic pathways.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels.
  • Type 2 diabetes mellitus (combination therapy): provides additional HbA1c reduction when added to metformin or sulfonylureas.
  • Type 2 diabetes mellitus (inadequately controlled): helps achieve target glycaemic goals alongside diet and exercise.

How It Works

  • Vildagliptin reversibly inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which degrades the incretin hormones GLP‑1 and GIP. By preventing this degradation, endogenous GLP‑1 and GIP levels rise, leading to glucose‑dependent enhancement of insulin secretion and suppression of glucagon release, thereby improving post‑prandial and overall glycaemic control.

Side Effects

Vildagliptin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Nausea: mild to moderate discomfort in the stomach.
  • Headache: occasional tension‑type headache.
  • Dizziness: transient light‑headedness, especially on standing.
  • Upper respiratory tract infection: mild cold‑like symptoms.
  • Abdominal pain: intermittent discomfort in the abdomen.
  • Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with vomiting, requiring immediate medical attention.
  • Severe allergic reactions: rash, itching, swelling, or anaphylaxis.
  • Hepatic dysfunction: elevated liver enzymes or jaundice.
  • Bullous skin reactions: blistering skin conditions.
  • Severe hypoglycaemia: prolonged loss of consciousness or seizures.

Precautions & Warnings

Before initiating therapy with Jalra, several safety considerations should be reviewed.

  • Renal impairment: adjust dose or avoid use in severe renal dysfunction.
  • Hepatic impairment: monitor liver function tests regularly.
  • Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia, monitor glucose closely.
  • History of pancreatitis: avoid use due to potential recurrence.
  • Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
  • Store at room temperature: keep in the original packaging, protect from moisture and heat.

Avoid Interactions

Vildagliptin can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: may cause severe hypoglycaemia.
  • Strong CYP450 inhibitors (e.g., ketoconazole): can increase vildagliptin plasma levels.
  • GLP‑1 receptor agonists: additive incretin effect may increase risk of gastrointestinal symptoms.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect glucose control, monitor blood sugar.
  • Rifampin: may reduce vildagliptin exposure, consider dose adjustment.
  • ACE inhibitors: monitor renal function when combined.

Frequently Asked Questions

Jalra contains vildagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus. It helps lower blood glucose levels by enhancing the body’s own incretin hormones, and is used alone or in combination with other antidiabetic agents as part of a comprehensive diabetes management plan.

Vildagliptin blocks the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of the incretin hormones GLP‑1 and GIP. Higher levels of these hormones increase insulin secretion and reduce glucagon release in a glucose‑dependent manner, leading to improved post‑prandial and overall glycaemic control.

The prescribed dose of Jalra is determined by the treating healthcare professional based on individual patient factors such as renal function, concomitant medications, and glycaemic targets. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety of vildagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Jalra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with sulfonylureas, vildagliptin has a lower risk of hypoglycaemia when used as monotherapy. Unlike metformin, it does not affect gastrointestinal tolerance as markedly. Its mechanism is distinct from insulin and GLP‑1 receptor agonists, offering an oral option that enhances endogenous incretin activity.

Jalra should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Jalra is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with water and not crushed or chewed unless specifically advised by a healthcare professional.

The most serious adverse events linked to vildagliptin include pancreatitis, severe allergic reactions, and rare cases of hepatic dysfunction. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver injury.

Jalra is contraindicated in patients with a known hypersensitivity to vildagliptin or any component of the formulation. It should also be avoided in individuals with a history of pancreatitis or severe renal impairment unless a specialist determines that benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Vildagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT